All posts by: Michael Zand

About Michael Zand

Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation – Labiotech.eu (blog)

Continue reading

2017-10-25 NEWS

Labiotech.eu (blog)

Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation
Labiotech.eu (blog)
The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding
FDA Orphan Drug Designation Granted to Hemophilia Gene Therapy; Clinical Studies to Begin SoonRare Disease Report (blog)
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of …Nasdaq

all 3 news articles »

Continue reading

2017-10-25 NEWS

Immunotherapy in Kidney Cancer
OncLive
Martin H. Voss, MD: There’s a longstanding tradition of using immunotherapy in the management of metastatic kidney cancer, and much of the biology really lends itself well to these approaches. We know that this tumor type is often highly infiltrated

Continue reading

2017-10-25 NEWS

Amid GMO Strife, Food Industry Vies For Public Trust In CRISPR Technology
KSUT Public Radio
The technology is called Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR. It’s a technique that Alison Van Eenennaam, an animal genetics professor at University of California, Davis, says can de-activate a gene. Or, as she puts it

Continue reading

2017-10-25 NEWS

NICE approves novel gene therapy for ‘bubble baby syndrome’
RCNi
NICE approves novel gene therapy for ‘bubble baby syndrome’. Matthew Mckew – @Matthew_MckewNS. Posted 24 October 2017 – 09:00. NICE issues draft guidance on therapy for children with very rare condition ADA-SCID. You need to sign in or register …